Royal Devon University Healthcare	
Data Protection Impact Assessment Toolkit	Version: 7
DPIA Reference	DPIA1402
DPIA Title	Use of data from central government bodies (NHSE, UKHSA and PHS) as part of the CLARITY-IBD study
Executive Summary of Proposal This is provided to Information Governance Steering Group and Safety and Risk as an overview of the project. It is also published on the website and should provide the public with an understanding	Use of data from central government bodies (NHSE, UKHSA and PHS) as part of the CLARITY-IBD study CLARITY IBD is a UK NIHR COVID19 urgent public health study (ISRCTN45176516) investigating the impact of biologic class and concomitant use of an immunomodulator on SARS-CoV-2 infection and immunity. Between 22/09/2020 and 23/12/2020, 7226 patients were recruited to this 64-week prospective observational study from 92 UK hospitals. Under COPI regulations study data has been linked to SARS-CoV-2 infection and vaccine data held by NHS England, UKHSA and Public Health Scotland. We wish to continue using paitent identifiable data linking SARS-CoV-2 vaccine and infection data with the study data until 30-6-23 and anonymised data for five years after. The CLARITY-IBD investigators wish to securely capture data on SARS-CoV-2 vaccination and infection data from NHS England, UKHSA and Public Health Scotland for participants of the CLARITY-IBD study. <b>1)Patient:</b> NHS number, Clarity-IBD number, name, date of birth, sex, date of centralised SARS-CoV2 PCR testing, SARS- CoV2 testing result, date of anti-SARS-CoV2 vaccination, type of anti-SARS-CoV2 vaccination, date of anti-Influenza vaccination, type of anti-SARS-CoV2 vaccination. <b>2)</b> [Blinical research investigating the impact of immumodulatory and biologic drugs on SARS-CoV-2 infection and immunity in patients with inflammatory bowel disease <b>3)D</b> ata sharing personnel at NHSE, UKHSA, PHS. Technical lead for CLARITY-IBD at RDUH <b>4)P</b> rocessing of personal data as part of data sharing from NHSE, UKHSA and PHS to CLARITY-IBD investigators <b>5)Bel</b> ates to current information on patients SARS-CoV-2 vaccination and infection status
Date Ratified	27 March 2023